More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$597107537
EPS
-2.27
P/E ratio
--
Price to sales
9.78
Dividend yield
--
Beta
1.044647
Previous close
$10.58
Today's open
$10.34
Day's range
$10.30 - $11.53
52 week range
$4.79 - $13.98
show more
CEO
Timothy T. Goodnow
Employees
130
Headquarters
Germantown, MD
Exchange
Nasdaq Global Select
Shares outstanding
54780508
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
BBNX & SENS Launch Eversense 365 Integration With iLet Bionic Pancreas
Beta Bionics launches iLet Bionic Pancreas integration with Eversense 365, offering more CGM options and boosting growth prospects in the diabetes care market.
Zacks Investment Research • 15 hours ago

Senseonics Holdings Sees $100 Million-Plus in 2027 Sales, Eyes New Eversense Launches
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS executives said the company's return of commercial operations in-house has improved efficiency and supported growth in its Eversense diabetes monitoring business, while outlining plans for new products and insulin pump partnerships.
MarketBeat • Nov 11, 2026

Senseonics Revenue Surges 140% as New Pump Integration Nears Launch
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS reported quarterly revenue of $19.6 million, up 140% from a year earlier, as the continuous glucose monitoring company expands access to its implantable Eversense sensor and prepares for a new insulin pump integration.
MarketBeat • Nov 12, 2026

Senseonics Holdings, Inc. (SENS) Q3 2026 Earnings Call Transcript
Senseonics Holdings, Inc. (SENS) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 10, 2026

What Senseonics Holdings, Inc. Common Stock (SENS) Said on Its Q3 Earnings Call
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS reported record third-quarter revenue and raised its 2026 sales outlook for the third time this year, as new patient starts for its Eversense 365 continuous glucose monitor drove growth in the United States and abroad.
MarketBeat • Nov 9, 2026

Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results
Generated third quarter revenue of $19.6 million, an increase of approximately 140% year-over-year Raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million, representing year-over-year growth of 93% to 98% Achieved gross margin of approximately 62% during Q3, and raising full-year gross margin guidance to more than 60% from 58% to 61% GERMANTOWN, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing technology, today announced third quarter 2026 financial results and provided a business update.
GlobeNewsWire • Nov 9, 2026

Senseonics Holdings (SENS) Reports Q3 Loss, Beats Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.43 per share a year ago.
Zacks Investment Research • Nov 10, 2026

Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World's First CGM System with No On-body Component
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics' innovation roadmap, with potential launch in 2028
GlobeNewsWire • Oct 26, 2026

Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November: Stifel 2026 Healthcare Conference – November 10-12, 2026 (New York, NY) Management will participate in a fireside chat at 3:20 pm ET and host one-on-one meetings with investors on Tuesday, November 10th.
GlobeNewsWire • Oct 22, 2026

Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2026 financial results after market close on Monday, November 9, 2026.
GlobeNewsWire • Oct 21, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Senseonics Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.